World News

The ACCESS-AD project launches in January 2026 with an ambitious goal to establish a collaborative, patient-centered approach to Alzheimer’s care throughout Europe.

Caldera raised USD75 million in a Series A financing round led by Atlas Venture, LAV, and venBio, followed by an additional USD37.5 million in a Series A-1 round led by Omega Funds.

The site will house the company’s signature technology: the fully automated Cell Shuttle production platform alongside Cell Q quality control systems.

The companies unveiled their partnership at the 2026 J.P. Morgan Healthcare Conference, which took place from January 12 to 15 in San Francisco.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.

Nimbus will leverage its specialized expertise in computational chemistry and structure-based drug design to discover a small molecule drug candidate.

Terumo plans to distribute the product to hospitals, clinics, and emergency care settings nationwide, making the technology widely accessible to medical professionals who perform injections daily.

The NMPA based its decision on compelling evidence from the TRIDENT-1 study, a pivotal Phase I/II clinical trial that demonstrated the drug’s effectiveness over time.

The sale came about following an unsolicited offer from BGH Capital, which focuses on investments in Australia and New Zealand.

The deal collapsed after STAAR failed to secure sufficient shareholder approval during a special stockholders meeting held on January 6.